PLRX
Pliant TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
The supported bull case is narrow: Pliant has runway into 2H 2028 and is advancing PLN-101095 after dosing the first FORTIFY participant, while Q1 materials described early anti-tumor activity and biomarker support in heavily pretreated solid tumors. [#PR-EARNINGS-2026-05-12][#SEC-8K-2026-05-11]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Despite runway into the second half of 2028, PLRX is still a sub-$100 million clinical-stage biotech and could face future financing or dilution pressure if development timelines extend.
Momentum
96
Value
58
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.50 · Bull $2.60 · Bear $0.60
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $2.50
Why
Momentum96 · Δ7d -
Value58 · Δ7d -0.1
Sentiment75 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
96
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
75
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.7 / Value 57.8 / Sentiment 75.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$71.21M
Beta
1.39
Shares Out
61.92M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.72
Rev YoY
-100.0%
EPS YoY
-64.7%
Gross Margin
-1160.5%
Op Margin
-
Net Debt
-$161.84M
Current Ratio
16.89
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology